Year Title Disease Area Modality Pipeline Stage
2024 Quantitative Systems Pharmacology Modeling of Adeno-Associated Virus Gene Therapies: Mechanistic Identification of Species-Translation Using Preclinical and Clinical Data (Chapter 4 in Development of Gene Therapies, eds. Avery McIntosh, Oleksandr Sverdlov) Rare diseases - hemophelia B Gene therapy Preclinical, Clinical
2024 In vitro evaluation of myelosuppressive effects of ATRi tuvusertib and ATMi lartesertib (M4076), alone and in combination. Cancer - various Small molecule Discovery
2024 Achieving Uniform Vector Genome Transduction in the Brain Tissue after Intraparenchymal Delivery of Adeno Associated Virus Gene Therapy Using Computational Fluid Dynamics and Quantitative Systems Pharmacology Modeling Neuorlogical - Huntington's disease Gene therapy Preclinical, Clinical
2022 Translational PK/PD/efficacy modeling and efficacious human dose prediction for a first-in-class MUC1-EGFR (M1231) bispecific antibody drug conjugate Cancer - various ADC Preclinical, Clinical
2021 Developing a robust Quantitative Systems Pharmacology model of adeno-associated virus (AAV) based gene therapy for clinical applications Rare diseases - hemophelia B Gene therapy Preclinical, Clinical
2020 A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics Various mAb Preclinical, Clinical
2020 Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1 Cancer ADC Preclinical, Clinical
2020 A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat Lysosomal diseases - Gaucher mAb Preclinical, Clinical
2020 Quantitative Systems Pharmacology Dissection of IL-4/IL-13 Contribution to Human Allergic IgE Production Allergic diseases such as asthma mAb Clinical
2020 Development of a QSP model for ADAMTS13 and von Willebrand factor interactions Rare diseases - thrombotic thrombocytopenic purpura (TTP) mAb Preclinical, Clinical
2020 Hereditary angioedema (HAE) prophylaxis with plasma kallikrein inhibitors: Role of target binding kinetics, pharmacokinetics and treatment adherence Rare diseases - hereditary angioedema (HAE) mAb Preclinical, Clinical
2019 A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data Various mAb Preclinical, Clinical
2019 Integrated efficacy-safety QSP model of acute myeloid leukemia (AML) generates insights into the role of clinical dose schedules on cytopenia Allergic diseases such as asthma Oncology - acute myeloid leukemia (AML) Clinical
2019 A mechanism-based translational mathematical model for gastrointestinal toxicity Oncology - gastrointestinal toxicity Small molecule Preclinical, Clinical
2018 Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules Cancer - gastrointestinal (GI) adverse events (AEs) Small molecule Preclinical, Clinical
2018 Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology Lysosomal diseases - acid sphingomyelinase deficiency (ASMD) mAb Clinical
2016 Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin Oncology - B cell malignancies including non-Hodgkin's lymphoma (NHL) and acute lymphocytic leukemia (ALL) ADC Preclinical, Clinical
2015 Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738 Oncology - many diseases, including ataxia telangiectasia (AT), chronic lymphocytic leukemia (CLL) and colorectal cancer (CRC) Small molecule Discovery, Preclinical, Clinical
2015 Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies Virology - hepatits C virus (HCV) Small molecule Clinical
2015 Optimization of an Aminothiazine Ring Formation: Integrating Modeling with Experiments to Maximize Yield by Minimizing Impurity Formation Various Small molecule Drug synthesis and manufacturing
2014 Modeling Tablet Dissolution in Complex Hydrodynamic Environments Various Small molecule Drug synthesis and manufacturing
2014 Modeling Population Heterogeneity in Viral Dynamics for Chronic Hepatitis C Infection: Insights from Phase 3 Telaprevir Clinical Studies Virology - hepatits C virus (HCV) Small molecule Clinical
2014 A Theoretical Approach to Modeling Renal Pharmacokinetics Various Small molecule Preclinical, Clinical
2012 A Viral Dynamic Model for Treatment Regimens with Direct-acting Antivirals for Chronic Hepatitis C Infection Virology - hepatits C virus (HCV) Small molecule Preclinical, Clinical
2011 Comprehensive mechanism-based antibody pharmacokinetic modeling Various mAb Preclinical, Clinical
2010 A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants Virology - hepatits C virus (HCV) Small molecule Preclinical, Clinical
2010 Modeling, Optimization, and Applications of Kinetic Mechanisms with OpenChem Various Small molecule Drug synthesis and manufacturing
2009 Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data Cancer - various mAb Discovery